Immunotherapy
Conditions
Keywords
NK cell infusion
Brief summary
This study is designed to explore the safety and efficacy of natural killer (NK) cell infusion as treatment for patients with advanced malignant tumors after multiline therapy, and to evaluate the pharmacokinetics of NK cells in patients
Interventions
BIOLOGICALNK cells infusion
Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment. NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times
Sponsors
Anhui Provincial Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with advanced malignant tumors diagnosed by pathological histology and/or cytology who have failed multi-line therapy and have no standard treatment method are unable to undergo surgery, radiation therapy, or chemotherapy; 2. Age 18-75 years old (≥18, ≤75); 3. ECOG: 0-1; 4. Priority should be given to the inclusion of ovarian cancer, malignant leukemia, lymphoma, etc. that have been shown to respond well to NK cell therapy; 5. Expected survival period ≥ 3 months; 6. Hematology tests also meet the following requirements: 1\) WBC≥3×109/L, ANC≥1.5×109/L, Hb≥90g/L, PLT≥100×109/L; 2) TBIL ≤ 1.5 × ULN (normal upper limit), ALT and AST ≤ 2 × ULN (if there is liver metastasis, then ≤ 5 × ULN); 3) Endogenous creatinine clearance ≥ 60 ml/min (calculated based on Cockcroft-Gault formula); (7) Length of solid tumors do not exceed 6 cm; (8) Signing of informed consent from each patient
Exclusion criteria
1. History of other malignancies with a disease-free period \<5 years (except for cured basal cell carcinoma of the skin, cured carcinoma of the cervix in situ, and gastrointestinal tumors proven to be cured by endoscopic mucosal resection); 2. Patients with brain metastases (unless the investigator believes that brain metastasis is currently stable, it is generally not recommended for enrollment); 3. Transplant recipients; 4. T-cell lymphoma patients; 5. Allergies to biologics used in this treatment; 6. Patients with HIV and syphilis; 7. HBV carriers; 8. Patients who are undergoing radiation therapy or immunotherapy within 4 weeks; 9. Patients who have undergone high-dose radiation therapy on the lung and liver within 4 months; 10. Patients with pulmonary inflammation determined by chest radiography; 11. Oxygen saturation ≤ 90% on room air; 12. Patients with cachexia caused by advanced tumors; 13. Long-term use of immunosuppressive drugs or patients who are using immunosuppressive drugs; 14. Those with serious autoimmune diseases; 15. Patients with organ failure (grade 4 of heart function; liver function with Child class C or above; brain metastasis with disturbance of consciousness; severe respiratory failure symptoms); 16. Active infections (including intra-abdominal infections). 17. Researchers consider it inappropriate to participate in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Successful expansion of NK cells in patient's circulatory system | 7 days after the last treatment | CD56 positive cells ≥100 cells/μL in blood is considered as successful expansion of NK cells |
| Objective Response Rate | 4 weeks after all the treatment finished | The percentage of patients who reach complete response（CR）or partial response （PR）after all treatment finished. The response is evaluated according to irRECIST. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 1 and 2 years after treatment | The interval time from the date when patients are enrolled into study to death or the last visit |
| Disease progression free survival | 1 and 2 years after treatment | The interval time from the date when patients are enrolled into study to disease progression, death or last visit |
| Dynamic changes of NK cells number in blood | Day 1,3,5,7,10,14,21,28 and 2, 3, 6 months after NK cells infusion finished | Numbers of CD56 positive cell in peripheral blood |
Countries
China
Contacts
Primary ContactYueyin Pan, PhD
Backup ContactWei Wang, MD
Outcome results
None listed